A Phase 1 interventional study of lansoprazole, 30 mg per day for 6 days in Healthy, sponsored by Xijing Hospital. Completed at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-03.
Sponsored by Xijing Hospital · Phase 1, Interventional, and Treatment
Oral hypoglycemic medications sometimes do not control type 2 diabetes well. Proton pump inhibitors (PPIs) as adjunctive therapy might improve diabetes control and could enhance the hypoglycemic activity of DPP4, but there is little clinical data on efficacy of this therapeutic strategy. The investigators sought to examine the effect of PPI lansoprazole, DPP-4 inhibitor sitagliptin, and their combination therapy on insulin and glucose regulation in healthy subjects in oral glucose tolerance (OGTT).
Oral hypoglycemic medications sometimes do not control type 2 diabetes well. Proton pump inhibitors (PPIs) as adjunctive therapy might improve diabetes control and could enhance the hypoglycemic activity of DPP4, but there is little clinical data on efficacy of this therapeutic strategy. We sought to examine the effect of PPI (lansoprazole), DPP4 (sitagliptin), and their combination therapy on insulin and glucose regulation in healthy subjects in oral glucose tolerance (OGTT).
Xijing Hospital is the lead sponsor of 465 studies on the registry; 157 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
oral sitagliptin 100 mg on day 6 after administration of placebo (30 mg per day) for 6 days
oral sitagliptin 100 mg on day 6 after administration of lansoprazole (30 mg per day) for 6 days
Drug: lansoprazole, 30 mg per day for 6 days
Also known as: Oral glucose tolerance test (OGTT)
Glucose Tolerance
Time frame: 0, 15, 30, 60, 90, 120, 180 min. after glucose administration
Plasma insulin and C-peptide concentrations during oral glucose tolerance test
Time frame: 0, 15, 30, 60, 90, 120, 180 min. after glucose administration
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xijing Hospital